Log in

Innate Pharma News Headlines (NASDAQ:IPHA)

$5.25
+0.15 (+2.94 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$4.90
Now: $5.25
$5.40
50-Day Range
$3.80
MA: $6.47
$7.95
52-Week Range
$3.30
Now: $5.25
$8.24
Volume7,423 shs
Average VolumeN/A
Market Capitalization$401.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Innate Pharma (NASDAQ IPHA) News Headlines

Source:
DateHeadline
Contrasting Innate Pharma (IPHA) & Its PeersContrasting Innate Pharma (IPHA) & Its Peers
www.americanbankingnews.com - March 29 at 3:50 AM
Head-To-Head Analysis: Innate Pharma (IPHA) and Its CompetitorsHead-To-Head Analysis: Innate Pharma (IPHA) and Its Competitors
www.americanbankingnews.com - March 23 at 10:48 PM
Innate Pharma (IPHA) vs. Its Competitors Head-To-Head ContrastInnate Pharma (IPHA) vs. Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - March 21 at 6:18 AM
Contrasting Innate Pharma (IPHA) & The CompetitionContrasting Innate Pharma (IPHA) & The Competition
www.americanbankingnews.com - March 18 at 8:48 AM
 Innate Pharma S.A. (NASDAQ:IPHA) Given $11.50 Consensus Target Price by Brokerages Innate Pharma S.A. (NASDAQ:IPHA) Given $11.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 14 at 12:01 PM
Contrasting Innate Pharma (IPHA) and Its RivalsContrasting Innate Pharma (IPHA) and Its Rivals
www.americanbankingnews.com - March 13 at 10:07 PM
Innate Pharma S.A. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?Innate Pharma S.A. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
finance.yahoo.com - March 13 at 8:07 AM
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumorsFirst patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
finance.yahoo.com - March 10 at 7:36 AM
IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL...IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL...
www.benzinga.com - February 10 at 11:07 PM
IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – IPHAIPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – IPHA
finance.yahoo.com - February 10 at 11:07 PM
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the FirmSHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - February 3 at 10:33 PM
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the FirmINVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - January 31 at 1:10 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm
www.businesswire.com - January 29 at 8:49 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHA
finance.yahoo.com - January 29 at 6:14 PM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHAEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA
finance.yahoo.com - January 29 at 6:14 PM
Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?
finance.yahoo.com - January 17 at 8:32 AM
French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoidesFrench regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides
finance.yahoo.com - January 13 at 8:44 PM
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoidesFrench Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
finance.yahoo.com - January 13 at 8:44 PM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innate Pharma S.A. (IPHA)Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innate Pharma S.A. (IPHA)
finance.yahoo.com - January 10 at 4:47 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA
www.globenewswire.com - January 10 at 1:21 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHA
finance.yahoo.com - January 10 at 1:21 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA
www.benzinga.com - January 9 at 10:31 PM
FDA places Innate Pharma lacutamab study on partial clinical holdFDA places Innate Pharma lacutamab study on partial clinical hold
seekingalpha.com - January 9 at 9:10 AM
Why This Hairy Cell Leukemia Treatment Could Be Big in EuropeWhy This Hairy Cell Leukemia Treatment Could Be Big in Europe
247wallst.com - January 3 at 4:34 PM
Innate Pharma up 27% premarket on EMA acceptance of Lumoxiti applicationInnate Pharma up 27% premarket on EMA acceptance of Lumoxiti application
seekingalpha.com - January 3 at 4:34 PM
Innate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia DrugInnate Pharma Rallies On Acceptance Of European Regulatory Application For Leukemia Drug
www.benzinga.com - January 3 at 4:34 PM
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel